N
Star Prestige Review

PRHSX T. Rowe Price Health Sciences

Author

Emily Wilson

Updated on March 15, 2026

The investment seeks long-term capital appreciation.
The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.